ule 3.19A.1

# **Appendix 3X**

#### **Initial Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	ntity BENITEC BIOPHARMA LIMITED	
ABN	64 068 943 662	

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Jerel A Banks
Date of appointment	26 October 2016

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

11/3/2002 Appendix 3X Page 1

<sup>+</sup> See chapter 19 for defined terms.

## Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest  Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities
Nant Capital LLC: Dr Jerel A Banks is the Chief Investment Officer of Nant Capital LLC	29,305,819

#### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

n/a

Appendix 3X Page 2 11/3/2002

<sup>+</sup> See chapter 19 for defined terms.